MiMedx to acquire Sanara MedTech for $35/share in cash and stock, ~$350M enterprise value

Sanara MedTech Inc.

• Sanara shareholders to receive $33 cash plus 0.4735 MiMedx shares per share, valued at $35 total.
• Total enterprise value approximately $350 million; transaction expected to close by July 2027.
• Over $20 million in anticipated annual run-rate cost synergies post-close.
• Stockholders holding ~38.9% of Sanara shares have agreed to vote in favor of the merger.
• Sanara will become a wholly-owned subsidiary of MiMedx; Sanara stock to be delisted from Nasdaq.